Icotinib hydrochloride is an orally administered small-molecule reversible tyrosine kinase inhibitor that has been independently researched and developed and has independent intellectual property rights in the People’s Republic of China. Clinical trials have demonstrated that the response to icotinib among advanced non-small-cell lung cancer (NSCLC) patients who received at least one platinum-based chemotherapy regimen was not inferior to gefitinib. Since being launched August 2011 in the People’s Republic of China, icotinib has been widely used in clinics, and has become an important treatment option for Chinese patients with advanced NSCLC. The present study presents the Phase I, II, and III clinical trials of icotinib and discusses current clinical applications in the People’s Republic of China and future research directions.

/pdf/treating-advanced-non-small-cell-lung-cancer-in-chinese-sojxdyg5p3.pdf

Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib

Objective To observe the efficacy,safety in treatment with icotinib as first- line therapy with advanced non-small cell lung cancer(NSCLC). Methods Twenty- one patients with advanced NSCLC were enrolled in the study. All the patients treated with icotinib 125 mg,po,three times a day. The response rate,clinical symptom and toxicity were observed until progression or unacceptable toxicity. Results No patient appeared complete response,nine patients appeared partial response,nine patients appeared stable disease and three patients had progressive disease. The objective response rate was42. 9 %,and the disease control rate was 85. 7 %. Median Time to Progress was 7. 2 months. The main toxicity were skin rash and diarrhea. Conclusion Icotinib as first- ling therapy is an effective in the treatmean of advanced non- small cell lung cancer. All of patients are well- tolerated.

He Qin

Papers

Clinical value in treatment with icotinib as first- line therapy in advanced non- small cell lung cancer